FDA Needs Three-Month Extension to Review Ironwood Drug

Ironwood Pharmaceuticals and New York’s Forest Laboratories today announced that the U.S. Food and Drug Administration has notified both companies that it requires a three-month extension to complete its review of data supporting a new drug application for the investigational drug linaclotide.
Boston Herald